Clinical Trial Update: Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for LM-302 plus Gemcitabine in CLDN18.2-positive pancreatic cancer; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LM-302

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Pancreatic Cancer, Chemotherapy Effect | Phase 2 | Status: NOT_YET_RECRUITING